Medical Imaging (MEDD) 10-K 17 Apr 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Apr. 10, 2017	Jun. 30, 2016
Document And Entity Information
Entity Registrant Name	MEDICAL IMAGING CORP.
Entity Central Index Key	1,370,804
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	No
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 1,086,059
Entity Common Stock, Shares Outstanding		26,506,481
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,016

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current Assets
Cash and Cash Equivalents	$ 85,455	$ 109,914
Accounts Receivable
Accounts Receivable, net	1,106,712	880,210
Prepaid Expenses	43,087	19,204
Total Current Assets	1,235,254	1,009,328
Property and Equipment, net	2,100,058	2,456,494
Goodwill	1,977,670	1,977,670
Deposits	18,563	11,764
TOTAL ASSETS	5,331,545	5,455,256
Current Liabilities
Accounts Payable	1,772,752	1,212,430
Accrued Liabilities	706,572	580,336
Current Portion of Capital Lease Obligations	123,738	205,740
Current Portion of Promissory Notes	931,842	409,789
Current Portion of Royalty Financing	752,926	106,141
Current Portion of Convertible Notes	2,223,706	156,425
Total Current Liabilities	6,511,536	2,670,861
Long Term Liabilities
Capital Lease Obligations, less current portion	200,536	267,146
Promissory Notes, less current portion	112,000	0
Royalty Financing, less current portion	1,254,498	1,828,960
Convertible Notes, less current portion	142,357	2,267,575
Total Liabilities	8,220,927	7,034,542
Commitments and Contingencies
Stockholders' Deficit
Preferred Stock	0	0
Common Stock	25,742	25,392
Additional Paid-In Capital	2,057,723	2,034,759
Accumulated Other Comprehensive Income	138,145	140,670
Accumulated Deficit	(5,110,992)	(3,780,106)
Total Stockholders' Deficit	(2,889,382)	(1,579,286)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 5,331,545	$ 5,455,256

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Preferred stock, par value in dollars	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value in dollars	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	25,741,481	25,391,481
Common stock, shares outstanding	25,741,481	25,391,481
Doubtful accounts, accounts receivable	$ 475,982	$ 331,475
Accumulated depreciation, property and equipment	1,562,471	998,224
Unamortized discount, promissory notes	120,000	128,047
Royalty financing, unamortized discount	5,302,853	5,618,680
Unamortized debt discount, convertible notes	$ 2,634	$ 31,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenue:
Sales	$ 7,179,085	$ 7,103,036
Cost of Sales	3,846,687	3,742,106
Gross Margin	3,332,398	3,360,930
Operating Expenses:
Labor	1,286,411	1,297,761
General and Administrative	752,725	746,222
Depreciation	561,077	546,338
Rent Office Space and Servers	550,241	551,268
Legal and Professional	280,353	390,300
Advertising	82,946	37,005
Insurance	90,174	92,055
Travel	45,840	41,067
Bad Debt Expense	146,047	290,209
Management Fees	20,400	33,613
Total Operating Expenses	3,816,214	4,025,838
Income from Operations	(483,816)	(664,908)
Other Income and (Expenses):
Other Income	78,020	68,174
Foreign Currency Gains (Losses)	62,196	(34,826)
Amortization of Debt Discount	(495,361)	(613,121)
Interest & Penalties Expense	(491,925)	(495,829)
Total Other Income (Expenses)	(847,070)	(1,075,602)
Net Loss	(1,330,886)	(1,740,510)
Comprehensive Income (Loss)	(2,525)	119,277
Total Comprehensive Loss	$ (1,333,411)	$ (1,621,233)
Basic and Diluted Loss per Share	$ (0.052)	$ (0.067)
Weighted Average Shares Outstanding - Basic and Diluted	25,585,931	24,159,122

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit - USD ($)	Common Stock	Additional Paid-In Capital	Other Comprehensive Income	Accumulated Deficit	Total
Beginning Balance at Dec. 31, 2014	$ 23,947	$ 1,876,484	$ 21,393	$ (2,039,596)	$ (117,772)
Beginning Balance, shares at Dec. 31, 2014	23,946,481
Change in Stockholders' Deficit
Shares issued for Services, value	$ 1,425	64,040			65,465
Shares issued for Services, shares	1,425,000
Shares Issued for Convertible Notes, value	$ 20	1,020			1,040
Shares Issued for Convertible Notes, shares	20,000
Comprehensive income/loss			119,277		119,277
Options issued		82,579			82,579
Warrants Issued		10,635			10,635
Net Loss				(1,740,510)	(1,740,510)
Ending Balance at Dec. 31, 2015	$ 25,392	2,034,758	140,670	(3,780,106)	(1,579,286)
Ending Balance, shares at Dec. 31, 2015	25,391,481
Change in Stockholders' Deficit
Shares issued for Services, value	$ 150	13,850			14,000
Shares issued for Services, shares	150,000
Shares Issued for Convertible Notes, value	$ 200	8,830			9,030
Shares Issued for Convertible Notes, shares	200,000
Comprehensive income/loss			(2,525)		(2,525)
Warrants Issued		285			285
Net Loss				(1,330,886)	(1,330,886)
Ending Balance at Dec. 31, 2016	$ 25,742	$ 2,057,723	$ 138,145	$ (5,110,992)	$ (2,889,382)
Ending Balance, shares at Dec. 31, 2016	25,741,481

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income (Loss)	$ (1,330,886)	$ (1,740,510)
Adjustments to Reconcile Net Loss to Net Cash provided by Operating Activities:
Depreciation	561,077	546,338
Amortization of Debt Discount	495,361	613,121
Stock-based compensation	14,000	148,044
Foreign currency transaction (Gain) Loss	(1,959)	(2,130)
Changes in operating assets and liabilities:
Accounts Receivable, Net of Allowance for Doubtful Accounts	(226,502)	(28,326)
Prepaid Expenses and Deposits	(28,506)	4,961
Loans Receivable	0	1,497
Accounts Payable and Accrued Liabilities	686,558	857,075
NET CASH AND CASH EQUIVALENTS FROM OPERATING ACTIVITIES	169,143	400,070
CASH FLOWS FROM INVESTING ACTIVITIES:
Equipment Purchase	(139,041)	(45,251)
NET CASH FROM INVESTING ACTIVITIES	(139,041)	(45,251)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from Promissory Notes	1,133,625	1,327,679
Proceeds from Convertible Debt	0	20,000
Royalty Fee Payment	(240,119)	(410,189)
Principal Payments on Promissory Notes	(651,158)	(1,234,549)
Principal Payments on Convertible Debt	(80,000)	(60,000)
Principal Payments on Capital Lease Obligations	(214,384)	(195,332)
NET CASH AND CASH EQUIVALENTS FROM FINANCING ACTIVITIES	(52,036)	(552,391)
Gain (Loss) Due to Foreign Currency Translation	(2,525)	119,277
NET CHANGE IN CASH AND CASH EQUIVALENTS	(24,459)	(78,295)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	109,914	188,209
CASH AND CASH EQUIVALENTS AT END OF PERIOD	85,455	109,914
Cash paid during the year for:
Interest	307,311	483,061
Income Taxes	51,187	27,280
Non-cash financing and investing activities:
Shares Issued for Convertible Note	9,030	1,040
Warrants Issued for Converted Notes	285	10,635
Equipment purchase under Capital Lease	64,618	18,384
Accrued Interest converted to Note	$ 0	$ 15,000

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Summary of Significant Accounting Policies	Note 1. Organization and Summary of Significant Accounting Policies Organization and Basis of Presentation Medical Imaging Corp., (“MIC” or the “Company”), a Nevada Corporation was incorporated in 2000. In 2005, the Company developed a business plan for private healthcare opportunities in Canada with the objective of owning and operating private diagnostic imaging clinics. In 2009, the Company purchased Canadian Teleradiology Services Inc., which operates as: Custom Teleradiology Services (“CTS”). CTS provides remote reading of medical diagnostic imaging scans for rural hospitals and clinics in Canada. In early 2010, the Company modified its business plan to grow its CTS subsidiary while commencing the acquisition of existing full service imaging clinics located in the United States and exploring the development of new diagnostic imaging technology. In 2012, the Company purchased Schuylkill Open MRI Inc., which operates as: Schuylkill Medical Imaging (“SMI”), an independent diagnostic imaging facility located in Pottsville, Pennsylvania. In 2014, the Company purchased Partners Imaging Center of Venice, LLC (“PIV”) located in Venice, Florida; Partners Imaging Center of Naples, LLC (“PIN”) located in Naples, Florida; and Partners Imaging Center of Charlotte, LLC (“PIC”) located in Port Charlotte, Florida. Basis of Presentation These consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States, and are expressed in U.S. dollars. The Company’s fiscal year-end is December 31. Principle of Consolidation The consolidated financial statements include the accounts of Medical Imaging, Corp., and its wholly-owned subsidiaries, CTS, SMI, PIV, PIN, and PIC. Intercompany accounts and transactions have been eliminated in the consolidated financial statements. CTS’, SMI’s, PIV’s, PIN’s, and PIC’s accumulated earnings prior to their acquisitions are not included in the consolidated balance sheet. Use of Estimates and Assumptions The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the consolidated financial statements are published, and (iii) the reported amount of net sales, expenses and costs recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of consolidated financial statements; accordingly, actual results could differ from these estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. At December 31, 2016, and 2015, cash includes cash on hand and cash in the bank. Accounts Receivable Credit Risk The allowance for doubtful accounts is maintained at a level sufficient to provide for estimated credit losses based on evaluating known and inherent risks in the receivables portfolio. Management evaluates various factors including expected losses and economic conditions to predict the estimated realization on outstanding receivables. In connection with the acquisition of the three facilities located in Venice, Port Charlotte and Naples, Florida, the Company, in October 2014, entered into professional services agreements whereby the seller of those three facilities continued to handle the billing and collection for the imaging centers (the “third party billing”). The seller must still provide a full set of verification data to the Company with respect to its account receivable processing and collections so that the Company can determine the extent to which accounts submitted by the seller in connection with the third party billing have been collected or denied. Final verification will only be able to be completed after the conclusion of the services performed pursuant to the third party billing contract, and review of account balances which is expected during the 2017 fiscal year. As of December 31, 2016, and 2015, the allowance for doubtful accounts from direct billings was $200,982 and $56,475, respectively. The allowance for doubtful accounts from third party billings (Florida operations) was $275,000 in both years. Although the gross receivable balance has increased significantly, management is actively pursuing collection efforts directly with patients and insurance payers and believes that the current allowance for doubtful accounts is sufficient to cover any expected losses. Goodwill and Indefinite Intangible Assets The Company follows the provisions of Financial Accounting Standard Accounting Standards Codification (“ASC”) 350, Goodwill and Other Intangible Assets No goodwill impairment was recognized during 2016 or 2015. Revenue Recognition The Company holds contracts with several hospitals and groups of health care facilities to provide Teleradiology services for a specific period of time. The Company bills for services rendered on a monthly basis. For the year ended December 31, 2016, CTS held six contracts; four contracts that are renewable on a year-to-year basis and one contract that renewed in 2016 and one to be renewed in 2018. In accordance with the requirement of Staff Accounting Bulletin (“SAB”) 104, the Company recognizes revenue when: (1) persuasive evidence of an arrangement exists (contracts); (2) delivery has occurred (monthly); (3) the seller’s price is fixed or determinable (per the customer’s contract, and services performed); and (4) collectability is reasonably assured (based upon our credit policy). Revenue is accounted for under the guidelines established by SAB 101, Revenue Recognition in Financial Statements, Revenue Recognition Cost of Sales Cost of sales includes fees paid to radiologists for reading services, transcription fees, equipment repairs, system license and usage costs. Impairment of Long-Lived Assets In accordance with ASC 360, Property, Plant and Equipment, Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Stock Based Compensation The Company follows ASC 718, Stock Compensation The Company measures all share-based payments to employees (which includes non-employee Board of Directors), including employee stock options, warrants and restricted stock, at the fair value of the award and expenses it over the requisite service period (generally the vesting period). The fair value of common stock options or warrants granted to employees is estimated at the date of grant using the binomial option pricing model (“BOPM”). The calculation also takes into account the common stock fair market value at the grant date, the exercise price, the expected life of the common stock option or warrant, the dividend yield and the risk-free interest rate. The Company from time to time may issue stock options, warrants and restricted stock to acquire goods or services from third parties. Restricted stock, options or warrants issued to other than employees or directors are recorded on the basis of their fair value. The options or warrants are valued using the BOPM on the basis of the market price of the underlying equity instrument on the “valuation date,” which for options and warrants related to contracts that have substantial disincentives to non-performance, is the date of the contract, and for all other contracts is the vesting date. Expenses related to the options and warrants are recognized on a straight-line basis over the period which services are to be received. There was no stock-based compensation expense to non-employees for the year ended December 31, 2016. For the year ended December 31, 2015, the Company recognized stock-based compensation expenses from stock granted to non-employees of $34,683 from stock options and $20,250 from stock issued. The options were valued using the BOPM and included in the legal and professional operating expenses in the consolidated statements of operations. For the year ended December 31, 2016, the Company recognized stock granted to employees of $14,000. For the year ended December 31, 2015, the Company recognized stock-based compensation expenses of $47,896 from stock options, and $45,215 from stock granted to employees. The options were valued using the BOPM and included in the labor and management fees operating expenses in the consolidated statements of operations for $34,683 and $13,213, respectively. Fair Value of Financial Instruments The fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties other than in a forced sale or liquidation. The carrying amounts of the Company’s financial instruments, including cash, accounts receivable, prepaid expenses, accounts payable, accrued liabilities and notes and loans payable approximate fair value due to their most maturities. Fair Value Measurements The Company follows ASC 820 for disclosures about fair value of its financial instruments and to measure the fair value of its financial instruments. ASC 820 establishes a framework for measuring fair value in U.S. GAAP, and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three levels of fair value hierarchy defined by ASC 820 are described below: Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 3 pricing inputs that are generally observable inputs and not corroborated by market data. The carrying amounts of the Company’s financial assets and liabilities, such as cash and accounts payable approximate their fair values because of the short maturity of these instruments. The Company does not have assets and liabilities that are carried at fair value on a recurring basis. Foreign Currency Translation The Company’s functional currency for its wholly-owned subsidiary, CTS, is the Canadian dollar, and their financial statements have been translated into U.S. dollars. The Canadian dollar based accounts of the Company’s foreign operations have been translated into United States dollars using the current rate method. Assets and liabilities of those operations are translated into U.S. dollars using exchange rates as of the balance sheet date; income and expenses are translated using the weighted average exchange rates for the reporting period. Translation adjustments are recorded as accumulated other comprehensive income (loss), a separate component of stockholders’ equity. The Company recognized a foreign currency gain (loss) on transactions from operations of $62,196 for the year ended December 31, 2016 and $(34,826) for the year ended December 31, 2015. The Company recognized other comprehensive income (loss) of $(2,525) for the year ended December 31, 2016 and $119,277 for the year ended December 31, 2015. Income Taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes Net Income (Loss) Per Share The Company follows the provisions of ASC 260, Earnings per Share Basic earnings per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock or conversion of notes into shares of the Company’s common stock that could increase the number of shares outstanding and lower the earnings per share of the Company’s common stock. This calculation is not done for periods in a loss position as this would be antidilutive. Recent Accounting Updates The Company does not expect the adoption of any recently issued accounting pronouncements to have a significant impact on its results of operations, financial position or cash flow. Reclassification of Accounts Certain prior period amounts have been reclassified to conform to December 31, 2016 presentation.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 2. Property and Equipment Property and equipment are stated at cost. Depreciation is calculated using the straight - line method over the estimated useful life of the assets. At December 31, 2016 and 2015, the major class of property and equipment were as follows: December 31, 2016 December 31, 2015 Estimated useful lives Computer/Office Equipment $ 474,887 $ 454,117 3-7 years Medical Equipment 2,329,872 2,156,820 3-7 years Leasehold Improvements 857,770 843,781 5-39 years Less: Accumulated Depreciation (1,562,471) (998,224) Net Book Value $ 2,100,058 $ 2,456,494 Depreciation expense was $561,077 and $546,338 for the year ended December 31, 2016 and 2015, respectively.

Operating Lease Commitments

Operating Lease Commitments	12 Months Ended
	Dec. 31, 2016
Leases, Operating [Abstract]
Operating Lease Commitments	Note 3. Operating Lease Commitments CTS has a lease commitment for its office space of approximately $2,450 minimum rental per month, not including utilities, realty taxes, and operating costs. The lease renewed in April 2013 for a period of five years and will expire in March 2018. CTS has sublet the space under the original lease to the end of its original term. In accordance with ASC 840, Leases, CTS has a lease commitment for its new office space in Toronto, Canada of approximately $2,600 minimum rental per month, not including utilities, realty taxes, and operating costs. The lease will expire April 30, 2021. SMI entered into a lease commitment for its office space in Pottsville, Pennsylvania. The lease will expire on July 30, 2021. Monthly rental amounts are $6,908 per month not including utilities, realty taxes, and operating costs. SMI has a lease for its x-ray equipment space in Pottsville, Pennsylvania. The lease term is seven years from commitment date of October 2014. Monthly lease payments are $3,000. SMI has a lease for use of x-ray equipment and space in Pottsville, Pennsylvania. The lease term is two years from commitment date of January 2016. Monthly lease payments are $2,000. PIV has a lease for office space in Venice, Florida. The lease will expire September 30, 2021. Monthly rental amounts are $13,170 per month. PIN has a lease for office space in Naples, Florida. The lease will expire January 1, 2020. Monthly rental amounts are $9,543 per month. PIC has a lease for office space in Port Charlotte, Florida. The lease will expire June 20, 2021. Monthly rental amounts are $5,512 per month. Expected future minimum lease commitments as of December 31, 2016: Year Total 2017 $ 481,050 2018 432,048 2019 427,969 2020 352,483 2021 216,357 Thereafter - $ 1,909,907

Capital Lease Obligations

Capital Lease Obligations	12 Months Ended
	Dec. 31, 2016
Leases, Capital [Abstract]
Capital Lease Obligations	Note 4. Capital Lease Obligations A detailed summary of the capital lease obligations is as follows: Description Monthly payments Maturity Date APR * December 31, 2016 Balance December 31, 2015 Balance SMI Two MRI Machines $ 11,013 8-Jul-16 10.52 % $ - $ 113,910 SMI X-Ray Machine 1,495 15-Aug-19 6.32 43,930 58,591 SMI PACS/RIS System 3,115 1-Nov-19 5.69 100,240 130,962 SMI Copier 135 1-Aug-18 27.63 2,144 - SMI Ascentrium 2,450 18-Nov-18 21.48 44,776 - PIV,PIN,PIC PACS/RIS 3,094 1-Jan-20 4.22 107,170 139,045 PIV,PIN,PIC Computers 813 1-Nov-17 10.52 8,509 16,920 PIV,PIN,PIC Digital Printers 423 24-Feb-19 9.90 9,856 - CTS Computers 554 2-Feb-18 2.25 % 7,649 13,458 Total $ 23,092 $ 324,274 $ 472,886 *Annual Percentage Rate (“APR”). Minimum future lease payments under the capital leases as of December 31, 2016 are as follow: Minimum Lease Payments Total 2017 $ 144,140 2018 125,031 2019 84,201 2020 3,094 Total minimum lease payments 356,466 Less amount representing interest 32,192 Present value of minimum lease payments 324,274 Less current portion of minimum lease payments 123,738 Long-term capital lease obligations at December 31, 2016 $ 200,536

Promissory Notes

Promissory Notes	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Promissory Notes	Note 5. Promissory Notes A detailed summary of the promissory notes is as follows: Issuance Date Maturity Date APR * Payment Amount Payments Frequency December 31, 2016 Face Value Balance December 31, 2015 Face Value Balance 21-Mar-11 18-Mar-16 6.00 % $ 1,295 Monthly $ - $ 7,752 16-Jun-15 5-Jul-16 41.00 509 Daily - 145,719 16-Jun-15 2-Mar-16 50.95 765 Daily - 72,365 4-Aug-15 5-Jan-16 20.00 13,000 Weekly - 13,000 22-Sep-15 29-Feb-16 20.00 13,000 Weekly - 169,000 22-Dec-15 29-Feb-16 20.00 13,000 Weekly - 130,000 16-Feb-16 23-Feb-17 12.00 1,000 Monthly 100,000 - 22-Feb-16 31-Aug-17 25.00 10,417 Monthly 500,000 - 22-Mar-16 22-Mar-17 12.00 700 Monthly 70,000 - 1-Jul-16 1-Aug-17 20.00 20,000 Monthly 400,000 - 3-Oct-16 27-Dec-17 42.09 % $ 2,255 Weekly 117,261 - Total Face Value 1,187,261 537,836 Unamortized Discount (143,419 ) (128,047 ) Total $ 1,043,842 $ 409,789 *Annual Percentage Rate (“APR”)

Convertible Notes

Convertible Notes	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Convertible Notes	Note 6. Convertible Notes On December 5, 2012 and March 27, 2013, the Company sold, through a private placement to accredited investors, three year 12% convertible notes (“Series B Notes”) in the aggregate principal amount of $1,865,000, and $365,000, respectively. The Notes pay interest at a rate of 12% per annum, payable to the holder at 1% per month, and are convertible into common shares of the Company at $0.10 per share. In addition, each purchaser of the Notes received shares dependent on the dollar amount of Notes purchased. The total number of shares of common stock issued was 5,315,000 shares. On December 1, 2015, the holders of $1,840,000 Series B Notes have agreed to extend the maturity date of the debt outstanding to July 1, 2017 from its original maturity date of December 31, 2015. As part of the extension the Company issued warrants to entitle the holders to purchase up to 1,840,000 shares of common stock at an exercise price of $0.07 per share at any time from December 1, 2015 to July 1, 2018. The Company has valued the warrants at $0.0058 per issued share, and recorded a total discount of $10,672 to be amortized over the 18-month extension period. On March 31, 2016, the holders of $50,000 Series B Notes have agreed to extend the maturity date of the debt outstanding to September 1, 2017 from its original maturity date of March 31, 2016. As part of the extension the Company issued warrants to entitle the holders to purchase up to 50,000 shares of common stock at an exercise price of $0.07 per share at any time from March 31, 2016 to September 30, 2018. The Company has valued the warrants at $0.00278 per issued share, and recorded a total discount of $139 to be amortized over the 18-month extension period. On March 31, 2016, the holder of $25,000 Series B Notes has agreed to extend the maturity date of the debt outstanding to September 1, 2019 from its original maturity date of March 31, 2016. As part of the extension the Company issued warrants to entitle the holders to purchase up to 25,000 shares of common stock at an exercise price of $0.07 per share at any time from March 31, 2016 to September 30, 2019. The Company has valued the warrants at $0.00583 per issued share, and recorded a total discount of $146 to be amortized over the 30-month extension period. On May 22, 2014, the Company sold, through private placement to accredited investors, three year 12% convertible notes (“Series C Notes”) in the aggregate principal amount of $95,000. The Notes bear interest at a rate of 12% per annum, payable to the holder at1% per month, with the principal amount due on May 31, 2017. The Notes are convertible into shares of the Company’s common stock at an initial conversion rate of $0.15 per share. In addition, each holder of Series C Notes received shares dependent on the dollar amount of Notes purchased. On August 25, 2014, October 31, 2014 and February 17, 2015, the Company sold an additional $75,000, $50,000 and $20,000, respectively of Series C Notes. The total number of shares of common stock issued was 240,000 shares. On March 26, 2014, the Company issued a $300,000 convertible note to a non-affiliate. The note pays interest at a rate of 12% per annum, payable to the holder at 1% per month. In addition to interest payments, the Company is making monthly payments of $5,000 towards the principal balance beginning June 1, 2014 until the note due date of February 27, 2018. The note is convertible into common shares of the Company at $0.15 per share. In addition, the purchaser of the note received 300,000 shares as part of the note agreement. As of December 31, 2016, principal balance of the note was $145,000. In accordance with ASC 470, Debt with conversion and other options, (“ASC 470”) In accordance with ASC 480, Distinguishing Liabilities from Equity, • The debt can be transferred without the transfer of the warrants. • The warrants can be transferred without the transfer of the debt. • The warrants can be exercised while debt still outstanding. In accordance with ASC 470, if the warrants are classified as equity, then the proceeds should be allocated based on the relative fair values of the base instrument and the warrants were valued at $0.0058 per issued share, and recorded a total discount of $10,672 to be amortized over 18 months’ extension period. A detailed summary of the convertible notes is as follows: Issuance Date Maturity Date APR Conversion Rate Monthly Payment December 31, 2016 Face Value Balance December 31, 2015 Face Value Balance 3-Dec-12 1-Jul-17 12.00 % $ 0.10 $ 250 $ 25,000 $ 25,000 3-Dec-12 1-Jul-17 12.00 0.10 750 75,000 75,000 27-Mar-13 1-Jul-17 12.00 0.10 500 50,000 50,000 3-Dec-12 1-Jul-17 12.00 0.10 500 50,000 50,000 3-Dec-12 1-Jul-17 12.00 0.10 250 25,000 25,000 3-Dec-12 1-Jul-17 12.00 0.10 250 25,000 25,000 3-Dec-12 1-Jul-17 12.00 0.10 250 25,000 25,000 3-Dec-12 1-Jul-17 12.00 0.10 15,000 1,500,000 1,500,000 3-Dec-12 1-Jul-17 12.00 0.10 500 50,000 50,000 3-Dec-12 1-Jul-17 12.00 0.10 150 15,000 15,000 3-Dec-12 1-Jul-18 12.00 0.10 5,750 75,000 75,000 3-Dec-12 31-Mar-16 12.00 0.10 - - 25,000 27-Mar-13 30-Sep-17 12.00 0.10 250 25,000 25,000 27-Mar-13 30-Sep-17 12.00 0.10 250 25,000 25,000 27-Mar-13 30-Sep-19 12.00 0.10 250 25,000 25,000 22-May-14 31-May-17 12.00 0.15 500 50,000 50,000 22-May-14 31-May-17 12.00 0.15 225 22,500 22,500 22-May-14 31-May-17 12.00 0.15 225 22,500 22,500 25-Aug-14 31-Jul-17 12.00 0.15 500 50,000 50,000 25-Aug-14 31-Jul-17 12.00 0.15 250 25,000 25,000 31-Oct-14 31-Oct-17 12.00 0.15 500 50,000 50,000 17-Feb-15 28-Feb-18 12.00 0.15 200 20,000 20,000 26-Mar-14 28-Feb-18 12.00 0.15 6,450 145,000 200,000 Total Face Value $ 2,375,000 $ 2,455,000 Unamortized Discount (8,937 ) (31,000 ) Total $ 2,366,063 $ 2,424,000 Following are maturities of the long –term debt as of December 31, 2016: Principal Payments 2017 $ 2,230,000 2018 120,000 2019 25,000 Total $ 2,375,000

Royalty Financing

Royalty Financing	12 Months Ended
	Dec. 31, 2016
Royalty Financing
Royalty Financing	Note 7. Royalty Financing On October 31, 2014, the Company entered into a royalty purchase agreement with Grenville Strategic Royalty Corp. (“Grenville”) for the amount of $2,000,000. The agreement calls for a monthly payment to Grenville based on a percentage of the total of certain revenue items and subject to a minimum payment amount until $8,000,000 has been paid. The amount financed is recorded net of discount to be amortized during the term. For the years ended December 31, 2016 and 2015, the Company has recorded discount amortization expense of $315,827 and $340,372, respectively. The balance as shown on the consolidated balance sheet as of December 31, 2016 was $2,007,424, net of $5,302,853 in unamortized discount. The balance as shown on the consolidated balance sheet as of December 31, 2015 was $1,935,101, net of $5,618,680 in unamortized discount. As of December 31, 2016, the Company paid a total of $689,723 in royalty payments, additionally the Company has accrued $181,096 in unpaid royalty fees from August to December 2016.

Income Tax

Income Tax	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Note 8. Income Taxes ASC 740 requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between consolidated financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. For the year ended December 31, 2016, the Company had a cumulative net operating loss carryover of approximately $1,839,366 available for U.S federal income tax, which expire beginning in 2017. The net operating loss carryovers may be subject to limitations under Internal Revenue Code due to significant changes in the Company’s ownership. The Company has provided a full valuation allowance against the full amount of the net operating loss benefit, since, in the opinion of management, based upon the earnings history of the Company, it is more likely than not that the benefits will not be realized. Deferred net tax asset (34%) consists of the following at December 31, 2016: 2016 2015 Deferred tax asset $ 1,515,712 $ 1,062,352 Less valuation allowance (1,515,712 ) (1,062,352 ) Net deferred tax asset $ - $ - A reconciliation between income taxes at statutory tax rates (34%) and the actual income tax provision for continuing operations as of December 31, 2016 follows: 2016 2015 Expected Provision (based on statutory rate) $ (453,360 ) $ (551,219 ) Increase to deferred tax valuation allowance for net operating loss carry forward 453,360 551,219 Net provision $ - $ - The Company has filed its tax returns through December 31, 2015, and filed for a six months extension on its December 31, 2016 tax return filing. The provisions of ASC 740 require companies to recognize in their financial statements the impact of a tax position if that position is more likely than not to be sustained upon audit, based upon the technical merits of the position. ASC 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken on a tax return. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods and disclosure. Management does not believe that the Company has any material uncertain tax positions requiring recognition or measurement in accordance with the provisions of ASC 740. The Company’s policy is to record interest and penalties on uncertain tax positions, if any, as income tax expense. All past six tax years for the Company remain subject to future examinations by the applicable taxing authorities.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	Note 9. Related Party Transactions During January 2015, the Company entered into an agreement with a company that is owned and controlled by a major shareholder to provide consulting services. Fees payable for performance of the consulting services are $10,000 per month. In addition to the monthly fees, the consultant was paid at signing of the agreement, four million two hundred thousand (4,200,000) options to purchase common stock of the client at an exercise price of $0.15 per share with an expiry date of December 31, 2019; details of the options recognition are disclosed in Note 10. On December 28, 2015, 450,000 shares of common stock were issued as compensation of $20,250 owed and outstanding towards the 2015 consulting agreement. Fees incurred to the related party consultant for the years ended December 31, 2016 and 2015 were $120,000, respectively, and are included as an expense in Legal and Professional fees in the accompanying statement of operations for the period.

Common Stock Transactions

Common Stock Transactions	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Common Stock Transactions	Note 10. Common Stock Transactions On November 28, 2016, 100,000 shares were issued for services valued at $9,000 based upon the closing price of the Company’s common stock at the grant date. On June 16, 2016, the Company issued 30,000 shares of common stock of the Company as part of the bridge convertible note to a private investor. The shares were valued at $609 based upon the closing price of the Company’s common stock at the grant date. On June 7, 2016, 50,000 shares were issued for services valued at $5,000 based upon the closing price of the Company’s common stock at the grant date. On March 22, 2016, the Company issued 70,000 shares of common stock of the Company as part of the bridge convertible note to a private investor. The shares were valued at $1,421 based upon the closing price of the Company’s common stock at the grant date. On February 18, 2016, the Company issued 100,000 shares of common stock of the Company as part of the bridge convertible note to a private investor. The shares were valued at $7,000 based upon the closing price of the Company’s common stock at the grant date. For the year ended December 31, 2015, 1,425,000 shares were issued for services valued at $65,465 based upon the closing price of the Company’s common stock at the grant date. For the year ended December 31, 2015, 20,000 shares were issued as part of Series C convertible note agreements. The shares were valued at $1,040 based upon the closing price of the Company’s common stock at the grant date. On December 1, 2015, the Company issued 1,840,000 warrants to holders of Series B convertible notes (see Note 6) as part of the agreements to extend the maturity dates of the notes. The warrants are exercisable at a price of $0.07 per full share at any time from December 1, 2015 to July 1, 2018. The Company has valued the warrants at a $0.0058 per issued share. On January 27, 2015, the Company granted options as considerations for services provided by the CEO of the Company. The options are to purchase up to 4,200,000 shares of common stock, with an exercise price equal to $0.15 per share. The options shall have a five (5) year term. Inputs used in Binomial Option Pricing model were as follow: stock price at grant date: $0.0517, exercise price $0.15, expected life of the option two and a half (2.5) years, volatility of 70%, and risk free rate of 0.03%. The options were recorded on the grant date at a value of $34,683. On January 27, 2015, the Company granted options as considerations for consulting services provided to the Company. The options are to purchase up to 4,200,000 shares of common stock, with an exercise price equal to $0.15 per share. The options shall have a five (5) year term. Inputs used in Binomial Option Pricing model were as follow: stock price at grant date: $0.0517, exercise price $0.15, expected life of the option two and a half (2.5) years, volatility of 70%, and risk free rate of 0.03%. The options were recorded on the grant date at a value of $34,683. On January 27, 2015, the Company granted options as considerations for services provided by the CFO of the Company. The options are to purchase up to 1,600,000 shares of common stock, with an exercise price equal to $0.15 per share. The options shall have a five (5) year term. Inputs used in Binomial Option Pricing model were as follow: stock price at grant date: $0.0517, exercise price $0.15, expected life of the option two and a half (2.5) years, volatility of 70%, and risk free rate of 0.03%. The options were recorded on the grant date at a value of $13,213.

Going Concern

Going Concern	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 11. Going Concern As shown in the accompanying consolidated financial statements, the Company incurred net comprehensive loss of $1,333,411, and $1,621,233 for the years ended December 31, 2016 and 2015, as well as a working capital deficit of $5,276,282 at December 31, 2016. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. Management plans to raise additional financing in order to continue its operations and fulfill its debt obligations in 2017, but there can be no assurances that the plan will be successful. These consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	Note 12. Subsequent Events On February 23, 2017, 765,000 shares were issued for services valued at $30,600 based upon the closing price of the Company’s common stock at the grant date. The Company evaluated subsequent events through the date the consolidated financial statements were issued.

Accounting Policies (Policies)

Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Organization and Basis of Presentation	Organization and Basis of Presentation Medical Imaging Corp., (“MIC” or the “Company”), a Nevada Corporation was incorporated in 2000. In 2005, the Company developed a business plan for private healthcare opportunities in Canada with the objective of owning and operating private diagnostic imaging clinics. In 2009, the Company purchased Canadian Teleradiology Services Inc., which operates as: Custom Teleradiology Services (“CTS”). CTS provides remote reading of medical diagnostic imaging scans for rural hospitals and clinics in Canada. In early 2010, the Company modified its business plan to grow its CTS subsidiary while commencing the acquisition of existing full service imaging clinics located in the United States and exploring the development of new diagnostic imaging technology. In 2012, the Company purchased Schuylkill Open MRI Inc., which operates as: Schuylkill Medical Imaging (“SMI”), an independent diagnostic imaging facility located in Pottsville, Pennsylvania. In 2014, the Company purchased Partners Imaging Center of Venice, LLC (“PIV”) located in Venice, Florida; Partners Imaging Center of Naples, LLC (“PIN”) located in Naples, Florida; and Partners Imaging Center of Charlotte, LLC (“PIC”) located in Port Charlotte, Florida. Basis of Presentation These consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States, and are expressed in U.S. dollars. The Company’s fiscal year-end is December 31.
Principle of Consolidation	Principle of Consolidation The consolidated financial statements include the accounts of Medical Imaging, Corp., and its wholly-owned subsidiaries, CTS, SMI, PIV, PIN, and PIC. Intercompany accounts and transactions have been eliminated in the consolidated financial statements. CTS’, SMI’s, PIV’s, PIN’s, and PIC’s accumulated earnings prior to their acquisitions are not included in the consolidated balance sheet.
Use of Estimates and Assumptions	Use of Estimates and Assumptions The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the consolidated financial statements are published, and (iii) the reported amount of net sales, expenses and costs recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of consolidated financial statements; accordingly, actual results could differ from these estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. At December 31, 2016, and 2015, cash includes cash on hand and cash in the bank.
Accounts Receivable Credit Risk	Accounts Receivable Credit Risk The allowance for doubtful accounts is maintained at a level sufficient to provide for estimated credit losses based on evaluating known and inherent risks in the receivables portfolio. Management evaluates various factors including expected losses and economic conditions to predict the estimated realization on outstanding receivables. In connection with the acquisition of the three facilities located in Venice, Port Charlotte and Naples, Florida, the Company, in October 2014, entered into professional services agreements whereby the seller of those three facilities continued to handle the billing and collection for the imaging centers (the “third party billing”). The seller must still provide a full set of verification data to the Company with respect to its account receivable processing and collections so that the Company can determine the extent to which accounts submitted by the seller in connection with the third party billing have been collected or denied. Final verification will only be able to be completed after the conclusion of the services performed pursuant to the third party billing contract, and review of account balances which is expected during the 2017 fiscal year.
Goodwill and Indefinite Intangible Assets	Goodwill and Indefinite Intangible Assets The Company follows the provisions of Financial Accounting Standard Accounting Standards Codification (“ASC”) 350, Goodwill and Other Intangible Assets
Revenue Recognition	Revenue Recognition The Company holds contracts with several hospitals and groups of health care facilities to provide Teleradiology services for a specific period of time. The Company bills for services rendered on a monthly basis. For the year ended December 31, 2016, CTS held six contracts; four contracts that are renewable on a year-to-year basis and one contract that renewed in 2016 and one to be renewed in 2018. In accordance with the requirement of Staff Accounting Bulletin (“SAB”) 104, the Company recognizes revenue when: (1) persuasive evidence of an arrangement exists (contracts); (2) delivery has occurred (monthly); (3) the seller’s price is fixed or determinable (per the customer’s contract, and services performed); and (4) collectability is reasonably assured (based upon our credit policy). Revenue is accounted for under the guidelines established by SAB 101, Revenue Recognition in Financial Statements, Revenue Recognition
Cost of Sales	Cost of Sales Cost of sales includes fees paid to radiologists for reading services, transcription fees, equipment repairs, system license and usage costs.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets In accordance with ASC 360, Property, Plant and Equipment, Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset.
Stock Based Compensation	Stock Based Compensation The Company follows ASC 718, Stock Compensation The Company measures all share-based payments to employees (which includes non-employee Board of Directors), including employee stock options, warrants and restricted stock, at the fair value of the award and expenses it over the requisite service period (generally the vesting period). The fair value of common stock options or warrants granted to employees is estimated at the date of grant using the binomial option pricing model (“BOPM”). The calculation also takes into account the common stock fair market value at the grant date, the exercise price, the expected life of the common stock option or warrant, the dividend yield and the risk-free interest rate. The Company from time to time may issue stock options, warrants and restricted stock to acquire goods or services from third parties. Restricted stock, options or warrants issued to other than employees or directors are recorded on the basis of their fair value. The options or warrants are valued using the BOPM on the basis of the market price of the underlying equity instrument on the “valuation date,” which for options and warrants related to contracts that have substantial disincentives to non-performance, is the date of the contract, and for all other contracts is the vesting date. Expenses related to the options and warrants are recognized on a straight-line basis over the period which services are to be received.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties other than in a forced sale or liquidation. The carrying amounts of the Company’s financial instruments, including cash, accounts receivable, prepaid expenses, accounts payable, accrued liabilities and notes and loans payable approximate fair value due to their most maturities.
Fair Value Measurements	Fair Value Measurements The Company follows ASC 820 for disclosures about fair value of its financial instruments and to measure the fair value of its financial instruments. ASC 820 establishes a framework for measuring fair value in U.S. GAAP, and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three levels of fair value hierarchy defined by ASC 820 are described below: Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 3 pricing inputs that are generally observable inputs and not corroborated by market data. The carrying amounts of the Company’s financial assets and liabilities, such as cash and accounts payable approximate their fair values because of the short maturity of these instruments.
Foreign Currency Translation	Foreign Currency Translation The Company’s functional currency for its wholly-owned subsidiary, CTS, is the Canadian dollar, and their financial statements have been translated into U.S. dollars. The Canadian dollar based accounts of the Company’s foreign operations have been translated into United States dollars using the current rate method. Assets and liabilities of those operations are translated into U.S. dollars using exchange rates as of the balance sheet date; income and expenses are translated using the weighted average exchange rates for the reporting period. Translation adjustments are recorded as accumulated other comprehensive income (loss), a separate component of stockholders’ equity.
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes
Net Income (Loss) Per Share	Net Income (Loss) Per Share The Company follows the provisions of ASC 260, Earnings per Share Basic earnings per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock or conversion of notes into shares of the Company’s common stock that could increase the number of shares outstanding and lower the earnings per share of the Company’s common stock. This calculation is not done for periods in a loss position as this would be antidilutive.
Recent Accounting Updates	Recent Accounting Updates The Company does not expect the adoption of any recently issued accounting pronouncements to have a significant impact on its results of operations, financial position or cash flow.
Reclassification of Accounts	Reclassification of Accounts Certain prior period amounts have been reclassified to conform to December 31, 2016 presentation.

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property Plant and Equipment	December 31, 2016 December 31, 2015 Estimated useful lives Computer/Office Equipment $ 474,887 $ 454,117 3-7 years Medical Equipment 2,329,872 2,156,820 3-7 years Leasehold Improvements 857,770 843,781 5-39 years Less: Accumulated Depreciation (1,562,471) (998,224) Net Book Value $ 2,100,058 $ 2,456,494

Operating Lease Commitments (Ta

Operating Lease Commitments (Tables)	12 Months Ended
	Dec. 31, 2016
Leases, Operating [Abstract]
Schedule of Operating Lease Commitments	Year Total 2017 $ 481,050 2018 432,048 2019 427,969 2020 352,483 2021 216,357 Thereafter - $ 1,909,907

Capital Lease Obligations (Tabl

Capital Lease Obligations (Tables)	12 Months Ended
	Dec. 31, 2016
Leases, Capital [Abstract]
Schedule of Capital Leased Assets	Description Monthly payments Maturity Date APR * December 31, 2016 Balance December 31, 2015 Balance SMI Two MRI Machines $ 11,013 8-Jul-16 10.52 % $ - $ 113,910 SMI X-Ray Machine 1,495 15-Aug-19 6.32 43,930 58,591 SMI PACS/RIS System 3,115 1-Nov-19 5.69 100,240 130,962 SMI Copier 135 1-Aug-18 27.63 2,144 - SMI Ascentrium 2,450 18-Nov-18 21.48 44,776 - PIV,PIN,PIC PACS/RIS 3,094 1-Jan-20 4.22 107,170 139,045 PIV,PIN,PIC Computers 813 1-Nov-17 10.52 8,509 16,920 PIV,PIN,PIC Digital Printers 423 24-Feb-19 9.90 9,856 - CTS Computers 554 2-Feb-18 2.25 % 7,649 13,458 Total $ 23,092 $ 324,274 $ 472,886
Schedule of Future Minimum Lease Payments for Capital Leases	Minimum Lease Payments Total 2017 $ 144,140 2018 125,031 2019 84,201 2020 3,094 Total minimum lease payments 356,466 Less amount representing interest 32,192 Present value of minimum lease payments 324,274 Less current portion of minimum lease payments 123,738 Long-term capital lease obligations at December 31, 2016 $ 200,536

Promissory Notes (Tables)

Promissory Notes (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Schedule of Promissory Notes	Issuance Date Maturity Date APR * Payment Amount Payments Frequency December 31, 2016 Face Value Balance December 31, 2015 Face Value Balance 21-Mar-11 18-Mar-16 6.00 % $ 1,295 Monthly $ - $ 7,752 16-Jun-15 5-Jul-16 41.00 509 Daily - 145,719 16-Jun-15 2-Mar-16 50.95 765 Daily - 72,365 4-Aug-15 5-Jan-16 20.00 13,000 Weekly - 13,000 22-Sep-15 29-Feb-16 20.00 13,000 Weekly - 169,000 22-Dec-15 29-Feb-16 20.00 13,000 Weekly - 130,000 16-Feb-16 23-Feb-17 12.00 1,000 Monthly 100,000 - 22-Feb-16 31-Aug-17 25.00 10,417 Monthly 500,000 - 22-Mar-16 22-Mar-17 12.00 700 Monthly 70,000 - 1-Jul-16 1-Aug-17 20.00 20,000 Monthly 400,000 - 3-Oct-16 27-Dec-17 42.09 % $ 2,255 Weekly 117,261 - Total Face Value 1,187,261 537,836 Unamortized Discount (143,419 ) (128,047 ) Total $ 1,043,842 $ 409,789 *Annual Percentage Rate (“APR”)

Convertible Notes (Tables)

Convertible Notes (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Schedule of Convertible Debt	Issuance Date Maturity Date APR Conversion Rate Monthly Payment December 31, 2016 Face Value Balance December 31, 2015 Face Value Balance 3-Dec-12 1-Jul-17 12.00 % $ 0.10 $ 250 $ 25,000 $ 25,000 3-Dec-12 1-Jul-17 12.00 0.10 750 75,000 75,000 27-Mar-13 1-Jul-17 12.00 0.10 500 50,000 50,000 3-Dec-12 1-Jul-17 12.00 0.10 500 50,000 50,000 3-Dec-12 1-Jul-17 12.00 0.10 250 25,000 25,000 3-Dec-12 1-Jul-17 12.00 0.10 250 25,000 25,000 3-Dec-12 1-Jul-17 12.00 0.10 250 25,000 25,000 3-Dec-12 1-Jul-17 12.00 0.10 15,000 1,500,000 1,500,000 3-Dec-12 1-Jul-17 12.00 0.10 500 50,000 50,000 3-Dec-12 1-Jul-17 12.00 0.10 150 15,000 15,000 3-Dec-12 1-Jul-18 12.00 0.10 5,750 75,000 75,000 3-Dec-12 31-Mar-16 12.00 0.10 - - 25,000 27-Mar-13 30-Sep-17 12.00 0.10 250 25,000 25,000 27-Mar-13 30-Sep-17 12.00 0.10 250 25,000 25,000 27-Mar-13 30-Sep-19 12.00 0.10 250 25,000 25,000 22-May-14 31-May-17 12.00 0.15 500 50,000 50,000 22-May-14 31-May-17 12.00 0.15 225 22,500 22,500 22-May-14 31-May-17 12.00 0.15 225 22,500 22,500 25-Aug-14 31-Jul-17 12.00 0.15 500 50,000 50,000 25-Aug-14 31-Jul-17 12.00 0.15 250 25,000 25,000 31-Oct-14 31-Oct-17 12.00 0.15 500 50,000 50,000 17-Feb-15 28-Feb-18 12.00 0.15 200 20,000 20,000 26-Mar-14 28-Feb-18 12.00 0.15 6,450 145,000 200,000 Total Face Value $ 2,375,000 $ 2,455,000 Unamortized Discount (8,937 ) (31,000 ) Total $ 2,366,063 $ 2,424,000
Schedule of Maturities of Long-term Debt	Principal Payments 2017 $ 2,230,000 2018 120,000 2019 25,000 Total $ 2,375,000

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets	2016 2015 Deferred tax asset $ 1,515,712 $ 1,062,352 Less valuation allowance (1,515,712 ) (1,062,352 ) Net deferred tax asset $ - $ -
Schedule of Effective Income Tax Rate Reconciliation	2016 2015 Expected Provision (based on statutory rate) $ (453,360 ) $ (551,219 ) Increase to deferred tax valuation allowance for net operating loss carry forward 453,360 551,219 Net provision $ - $ -

Organization and Summary of S26

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Accounts Receivable, Net, Current
Allowance for doubtful accounts	$ 200,982	$ 56,475
Allowance for Doubtful Accounts - Third Party Billings (Florida Operations)	275,000	275,000
Recognized Share-Based Compensation Expense
Value of options granted included in labor fees operating expenses	1,286,411	1,297,761
Foreign Currency Translation
Foreign currency loss	62,196	(34,826)
Other comprehensive gain	(2,525)	119,277
Employee Stock
Recognized Share-Based Compensation Expense
Stock-based compensation expense, employees		45,215
Stock granted, value	$ 14,000
Value of options granted included in labor fees operating expenses		13,213
Employee Stock Option
Recognized Share-Based Compensation Expense
Stock-based compensation expense, employees		47,896
Value of options granted included in labor fees operating expenses		34,683
Non-Employee Stock
Recognized Share-Based Compensation Expense
Stock-based compensation expense, non-employees		20,250
Non-Employee Stock Option
Recognized Share-Based Compensation Expense
Stock-based compensation expense, non-employees		$ 34,683

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property and equipment, accumulated depreciation	$ (1,562,471)	$ (998,224)
Property and equipment, net	2,100,058	2,456,494
Computer/Office Equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 474,887	$ 454,117
Property and equipment, estimated useful lives	3-7 years	3-7 years
Medical Equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 2,329,872	$ 2,156,820
Property and equipment, estimated useful lives	3-7 years	3-7 years
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 857,770	$ 843,781
Property and equipment, estimated useful lives	5-39 years	5-39 years

Property and Equipment (Detai28

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 561,077	$ 546,338

Operating Lease Commitments (De

Operating Lease Commitments (Details)	Dec. 31, 2016USD ($)
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity
Year 2,017	$ 481,050
Year 2,018	432,048
Year 2,019	427,969
Year 2,020	352,483
Year 2,021	216,357
Thereafter	0
Operating Leases, Future Minimum Payments Due	$ 1,909,907

Operating Lease Commitments (30

Operating Lease Commitments (Details Narrative)	12 Months Ended
	Dec. 31, 2016USD ($)
CTS - Office Space
Operating lease, minimum payments	$ 2,450
Leasing arrangements	CTS has a lease commitment for its office space of approximately $2,450 minimum rental per month, not including utilities, realty taxes, and operating costs. The Lease renewed in April 2013 for a period of five years and will expire in March 2018.
Loss on sublease	$ 8,000
CTS - Office Space - Toronto, Canada
Operating lease, minimum payments	$ 2,600
Leasing arrangements	CTS has a lease commitment for its new office space in Toronto, Canada of approximately $2,600 minimum rental, not including utilities, realty taxes, and operating costs. The lease will expire April 30, 2021.
SMI - Office Space - Pottsville, Pennsylvania
Operating lease, minimum payments	$ 6,908
Leasing arrangements	SMI entered into a lease commitment for its office space in Pottsville, Pennsylvania. The lease will expire on July 30, 2021. Monthly rental amounts are $6,908 per month not including utilities, realty taxes, and operating costs.
SMI - X-Ray Equipment
Operating lease, minimum payments	$ 3,000
Leasing arrangements	Lease for x-ray equipment space. The lease term is seven years from commitment date of October 2014.
SMI - X-Ray Equipment #2
Operating lease, minimum payments	$ 2,000
Leasing arrangements	Lease for use of x-ray equipment and space. The lease term is two years from commitment date of January 2016.
Lease Arrangement | PIC
Operating lease, minimum payments	$ 5,512
Leasing arrangements	PIC has a lease for office space in Port Charlotte, Florida. The lease will expire June 20, 2021.
Lease Arrangement | PIN
Operating lease, minimum payments	$ 9,543
Leasing arrangements	PIN has a lease for office space in Naples, Florida. The lease will expire January 1, 2020.
Lease Arrangement | PIV
Operating lease, minimum payments	$ 13,170
Leasing arrangements	PIV has a lease for office space in Venice, Florida. The lease will expire September 30, 2021.

Capital Lease Obligations - Sch

Capital Lease Obligations - Schedule of Capital Leased Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Capital leases, present value	$ 324,274	$ 472,886
Capital leases, monthly payments	23,092
SMI - MRI
Capital leases, present value		113,910
Capital leases, monthly payments		$ 11,013
Capital leases, maturity date		Jul. 8, 2016
Capital leases, annual percentage rate		10.52%
SMI - X-Ray Lease
Capital leases, present value	43,930	$ 58,591
Capital leases, monthly payments	$ 1,495	$ 1,495
Capital leases, maturity date	Aug. 15, 2019	Aug. 15, 2019
Capital leases, annual percentage rate	6.32%	6.32%
SMI - PACS/RIS Lease
Capital leases, present value	$ 100,240	$ 130,962
Capital leases, monthly payments	$ 3,115	$ 3,115
Capital leases, maturity date	Nov. 1, 2019	Nov. 1, 2019
Capital leases, annual percentage rate	5.69%	5.69%
SMI Copier Lease
Capital leases, present value	$ 2,144
Capital leases, monthly payments	$ 135
Capital leases, maturity date	Aug. 1, 2018
Capital leases, annual percentage rate	27.63%
SMI Ascentrium
Capital leases, present value	$ 44,776
Capital leases, monthly payments	$ 2,450
Capital leases, maturity date	Nov. 18, 2018
Capital leases, annual percentage rate	21.48%
PV, PN, PC PACS/RIS Lease
Capital leases, present value	$ 107,170	$ 139,045
Capital leases, monthly payments	$ 3,094	$ 3,094
Capital leases, maturity date	Jan. 1, 2020	Jan. 1, 2020
Capital leases, annual percentage rate	4.22%	4.22%
PV, PN, PC Computers Lease
Capital leases, present value	$ 8,509	$ 16,920
Capital leases, monthly payments	$ 813	$ 813
Capital leases, maturity date	Nov. 1, 2017	Nov. 1, 2017
Capital leases, annual percentage rate	10.52%	10.52%
PV, PN, PC Digital Printers Lease
Capital leases, present value	$ 9,856
Capital leases, monthly payments	$ 423
Capital leases, maturity date	Feb. 24, 2019
Capital leases, annual percentage rate	9.90%
CTS Computers Lease
Capital leases, present value	$ 7,649	$ 13,458
Capital leases, monthly payments	$ 554	$ 554
Capital leases, maturity date	Feb. 2, 2018	Feb. 2, 2018
Capital leases, annual percentage rate	2.25%	2.25%

Capital Lease Obligations - S32

Capital Lease Obligations - Schedule of Future Minimum Lease Payments (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Capital Leases Future Minimum Payments
Minimum lease payments, 2017	$ 144,140
Minimum lease payments, 2018	125,031
Minimum lease payments, 2019	84,201
Minimum lease payments, 2020	3,094
Total minimum lease payments	356,466
Less amount representing interest	32,192
Present value of minimum lease payments	324,274	$ 472,886
Less current portion of minimum lease payments	123,738	205,740
Long-term Capital Lease Obligations at December 31, 2016	$ 200,536	$ 267,146

Promissory Notes (Details)

Promissory Notes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Short-term Debt [Line Items]
Promissory notes, balance	$ 1,187,261	$ 537,836
Unamortized Discount	$ (143,419)	$ (128,047)
Promissory Note #1
Short-term Debt [Line Items]
Promissory note, issuance date		Mar. 21, 2011
Promissory note, maturity date		Mar. 18, 2016
Promissory note, interest rate		6.00%
Promissory notes, payments		$ 1,295
Promissory notes, payment frequency		Monthly
Promissory notes, balance		$ 7,752
Promissory Note #2
Short-term Debt [Line Items]
Promissory note, issuance date		Jun. 16, 2015
Promissory note, maturity date		Jul. 5, 2016
Promissory note, interest rate		41.00%
Promissory notes, payments		$ 509
Promissory notes, payment frequency		Daily
Promissory notes, balance		$ 145,719
Promissory Note #3
Short-term Debt [Line Items]
Promissory note, issuance date		Jun. 16, 2015
Promissory note, maturity date		Mar. 2, 2016
Promissory note, interest rate		50.95%
Promissory notes, payments		$ 765
Promissory notes, payment frequency		Daily
Promissory notes, balance		$ 72,365
Promissory Note #4
Short-term Debt [Line Items]
Promissory note, issuance date		Aug. 4, 2015
Promissory note, maturity date		Jan. 5, 2016
Promissory note, interest rate		20.00%
Promissory notes, payments		$ 13,000
Promissory notes, payment frequency		Weekly
Promissory notes, balance		$ 13,000
Promissory Note #5
Short-term Debt [Line Items]
Promissory note, issuance date		Sep. 22, 2015
Promissory note, maturity date		Feb. 29, 2016
Promissory note, interest rate		20.00%
Promissory notes, payments		$ 13,000
Promissory notes, payment frequency		Weekly
Promissory notes, balance		$ 169,000
Promissory Note #6
Short-term Debt [Line Items]
Promissory note, issuance date		Dec. 22, 2015
Promissory note, maturity date		Feb. 29, 2016
Promissory note, interest rate		20.00%
Promissory notes, payments		$ 13,000
Promissory notes, payment frequency		Weekly
Promissory notes, balance		$ 130,000
Promissory Note #7
Short-term Debt [Line Items]
Promissory note, issuance date	Feb. 16, 2016
Promissory note, maturity date	Feb. 23, 2017
Promissory note, interest rate	12.00%
Promissory notes, payments	$ 1,000
Promissory notes, payment frequency	Monthly
Promissory notes, balance	$ 100,000
Promissory Note #8
Short-term Debt [Line Items]
Promissory note, issuance date	Feb. 22, 2016
Promissory note, maturity date	Aug. 31, 2017
Promissory note, interest rate	25.00%
Promissory notes, payments	$ 10,417
Promissory notes, payment frequency	Monthly
Promissory notes, balance	$ 500,000
Promissory Note #9
Short-term Debt [Line Items]
Promissory note, issuance date	Mar. 22, 2016
Promissory note, maturity date	Mar. 22, 2017
Promissory note, interest rate	12.00%
Promissory notes, payments	$ 700
Promissory notes, payment frequency	Monthly
Promissory notes, balance	$ 70,000
Promissory Note #10
Short-term Debt [Line Items]
Promissory note, issuance date	Jul. 1, 2016
Promissory note, maturity date	Aug. 1, 2017
Promissory note, interest rate	20.00%
Promissory notes, payments	$ 20,000
Promissory notes, payment frequency	Monthly
Promissory notes, balance	$ 400,000
Promissory Note #11
Short-term Debt [Line Items]
Promissory note, issuance date	Oct. 3, 2016
Promissory note, maturity date	Dec. 27, 2017
Promissory note, interest rate	42.09%
Promissory notes, payments	$ 2,255
Promissory notes, payment frequency	Weekly
Promissory notes, balance	$ 117,261

Convertible Notes - Schedule of

Convertible Notes - Schedule of Convertible Debt (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Convertible note, monthly payment	$ 80,000	$ 60,000
Convertible Notes
Debt Instrument [Line Items]
Convertible note, balance	$ 2,366,063	$ 2,424,000
Convertible Notes | Note #8
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012	Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2017	Jul. 1, 2017
Convertible note, interest rate	12.00%	12.00%
Convertible note, conversion rate	0.10%	0.10%
Convertible note, monthly payment	$ 15,000	$ 15,000
Convertible note, balance	$ 1,500,000	$ 1,500,000
Convertible Notes | Note #7
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012	Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2017	Jul. 1, 2017
Convertible note, interest rate	12.00%	12.00%
Convertible note, conversion rate	0.10%	0.10%
Convertible note, monthly payment	$ 250	$ 250
Convertible note, balance	$ 25,000	$ 25,000
Convertible Notes | Note #6
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012	Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2017	Jul. 1, 2017
Convertible note, interest rate	12.00%	12.00%
Convertible note, conversion rate	0.10%	0.10%
Convertible note, monthly payment	$ 250	$ 250
Convertible note, balance	$ 25,000	$ 25,000
Convertible Notes | Note #5
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012	Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2017	Jul. 1, 2017
Convertible note, interest rate	12.00%	12.00%
Convertible note, conversion rate	0.10%	0.10%
Convertible note, monthly payment	$ 250	$ 250
Convertible note, balance	$ 25,000	$ 25,000
Convertible Notes | Note #4
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012	Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2017	Jul. 1, 2017
Convertible note, interest rate	12.00%	12.00%
Convertible note, conversion rate	0.10%	0.10%
Convertible note, monthly payment	$ 500	$ 500
Convertible note, balance	$ 50,000	$ 50,000
Convertible Notes | Note #3
Debt Instrument [Line Items]
Convertible note, issuance date	Mar. 27, 2013	Mar. 27, 2013
Convertible note, maturity date	Jul. 1, 2017	Jul. 1, 2017
Convertible note, interest rate	12.00%	12.00%
Convertible note, conversion rate	0.10%	0.10%
Convertible note, monthly payment	$ 500	$ 500
Convertible note, balance	$ 50,000	$ 50,000
Convertible Notes | Note #2
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012	Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2017	Jul. 1, 2017
Convertible note, interest rate	12.00%	12.00%
Convertible note, conversion rate	0.10%	0.10%
Convertible note, monthly payment	$ 750	$ 750
Convertible note, balance	$ 75,000	$ 75,000
Convertible Notes | Note #1
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012	Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2017	Jul. 1, 2017
Convertible note, interest rate	12.00%	12.00%
Convertible note, conversion rate	0.10%	0.10%
Convertible note, monthly payment	$ 250	$ 250
Convertible note, balance	$ 25,000	$ 25,000

Convertible Notes - Schedule 35

Convertible Notes - Schedule of Convertible Debt, Continued #2 (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Convertible note, monthly payment	$ 80,000	$ 60,000
Convertible Notes
Debt Instrument [Line Items]
Convertible note, balance	$ 2,375,000	$ 2,455,000
Convertible Notes | Note #16
Debt Instrument [Line Items]
Convertible note, issuance date	May 22, 2014	May 22, 2014
Convertible note, maturity date	May 31, 2017	May 31, 2017
Convertible note, interest rate	12.00%	12.00%
Convertible note, conversion rate	0.15%	0.15%
Convertible note, monthly payment	$ 500	$ 500
Convertible note, balance	$ 50,000	$ 50,000
Convertible Notes | Note #15
Debt Instrument [Line Items]
Convertible note, issuance date	Mar. 27, 2013	Mar. 27, 2013
Convertible note, maturity date	Sep. 30, 2019	Sep. 30, 2019
Convertible note, interest rate	12.00%	12.00%
Convertible note, conversion rate	0.10%	0.10%
Convertible note, monthly payment	$ 250	$ 250
Convertible note, balance	$ 25,000	$ 25,000
Convertible Notes | Note #14
Debt Instrument [Line Items]
Convertible note, issuance date	Mar. 27, 2013	Mar. 27, 2013
Convertible note, maturity date	Sep. 30, 2017	Sep. 30, 2017
Convertible note, interest rate	12.00%	12.00%
Convertible note, conversion rate	0.10%	0.10%
Convertible note, monthly payment	$ 250	$ 250
Convertible note, balance	$ 25,000	$ 25,000
Convertible Notes | Note #13
Debt Instrument [Line Items]
Convertible note, issuance date	Mar. 27, 2013	Mar. 27, 2013
Convertible note, maturity date	Sep. 30, 2017	Sep. 30, 2017
Convertible note, interest rate	12.00%	12.00%
Convertible note, conversion rate	0.10%	0.10%
Convertible note, monthly payment	$ 250	$ 250
Convertible note, balance	$ 25,000	$ 25,000
Convertible Notes | Note #12
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012	Dec. 3, 2012
Convertible note, maturity date	Mar. 31, 2016	Mar. 31, 2016
Convertible note, interest rate	12.00%	12.00%
Convertible note, conversion rate	0.10%	0.10%
Convertible note, monthly payment	$ 0
Convertible note, balance	$ 0	$ 25,000
Convertible Notes | Note #11
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012	Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2018	Jul. 1, 2018
Convertible note, interest rate	12.00%	12.00%
Convertible note, conversion rate	0.10%	0.10%
Convertible note, monthly payment	$ 5,750	$ 5,750
Convertible note, balance	$ 75,000	$ 75,000
Convertible Notes | Note #10
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012	Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2017	Jul. 1, 2017
Convertible note, interest rate	12.00%	12.00%
Convertible note, conversion rate	0.10%	0.10%
Convertible note, monthly payment	$ 150	$ 150
Convertible note, balance	$ 15,000	$ 15,000
Convertible Notes | Note #9
Debt Instrument [Line Items]
Convertible note, issuance date	Dec. 3, 2012	Dec. 3, 2012
Convertible note, maturity date	Jul. 1, 2017	Jul. 1, 2017
Convertible note, interest rate	12.00%	12.00%
Convertible note, conversion rate	0.10%	0.10%
Convertible note, monthly payment	$ 500	$ 500
Convertible note, balance	$ 50,000	$ 50,000

Convertible Notes - Schedule 36

Convertible Notes - Schedule of Convertible Debt, Continued #3 (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Convertible note, monthly payment	$ 80,000	$ 60,000
Convertible note, unamortized debt discount	(143,419)	(128,047)
Convertible Notes
Debt Instrument [Line Items]
Convertible note, balance	2,375,000	2,455,000
Convertible note, unamortized debt discount	(8,937)	(31,000)
Convertible note, total	$ 2,366,063	$ 2,424,000
Convertible Notes | Note #23
Debt Instrument [Line Items]
Convertible note, issuance date	Mar. 26, 2014	Mar. 26, 2014
Convertible note, maturity date	Feb. 28, 2018	Feb. 28, 2018
Convertible note, interest rate	12.00%	12.00%
Convertible note, conversion rate	0.15%	0.15%
Convertible note, monthly payment	$ 6,450	$ 6,450
Convertible note, balance	$ 145,000	$ 145,000
Convertible Notes | Note #22
Debt Instrument [Line Items]
Convertible note, issuance date	Feb. 17, 2015	Feb. 17, 2015
Convertible note, maturity date	Feb. 28, 2018	Feb. 28, 2018
Convertible note, interest rate	12.00%	12.00%
Convertible note, conversion rate	0.15%	0.15%
Convertible note, monthly payment	$ 200	$ 200
Convertible note, balance	$ 20,000	$ 20,000
Convertible Notes | Note #21
Debt Instrument [Line Items]
Convertible note, issuance date	Oct. 31, 2014	Oct. 31, 2014
Convertible note, maturity date	Oct. 31, 2017	Oct. 31, 2017
Convertible note, interest rate	12.00%	12.00%
Convertible note, conversion rate	0.15%	0.15%
Convertible note, monthly payment	$ 500	$ 500
Convertible note, balance	$ 50,000	$ 50,000
Convertible Notes | Note #20
Debt Instrument [Line Items]
Convertible note, issuance date	Aug. 25, 2014	Aug. 25, 2014
Convertible note, maturity date	Jul. 31, 2017	Jul. 31, 2017
Convertible note, interest rate	12.00%	12.00%
Convertible note, conversion rate	0.15%	0.15%
Convertible note, monthly payment	$ 250	$ 250
Convertible note, balance	$ 25,000	$ 25,000
Convertible Notes | Note #19
Debt Instrument [Line Items]
Convertible note, issuance date	Aug. 25, 2014	Aug. 25, 2014
Convertible note, maturity date	Jul. 31, 2017	Jul. 31, 2017
Convertible note, interest rate	12.00%	12.00%
Convertible note, conversion rate	0.15%	0.15%
Convertible note, monthly payment	$ 500	$ 500
Convertible note, balance	$ 50,000	$ 50,000
Convertible Notes | Note #18
Debt Instrument [Line Items]
Convertible note, issuance date	May 22, 2017	May 22, 2017
Convertible note, maturity date	May 31, 2017	May 31, 2017
Convertible note, interest rate	12.00%	12.00%
Convertible note, conversion rate	0.15%	0.15%
Convertible note, monthly payment	$ 225	$ 225
Convertible note, balance	$ 22,500	$ 22,500
Convertible Notes | Note #17
Debt Instrument [Line Items]
Convertible note, issuance date	May 22, 2014	May 22, 2014
Convertible note, maturity date	May 31, 2017	May 31, 2017
Convertible note, interest rate	12.00%	12.00%
Convertible note, conversion rate	0.15%	0.15%
Convertible note, monthly payment	$ 225	$ 225
Convertible note, balance	$ 22,500	$ 22,500

Convertible Notes - Schedule 37

Convertible Notes - Schedule of Long-Term Debt Maturities (Details)	Dec. 31, 2016USD ($)
Debt Disclosure [Abstract]
Principal payments, 2017	$ 2,230,000
Principal payments, 2018	120,000
Principal payments, 2019	25,000
Total principal payments	$ 2,375,000

Convertible Notes (Details Narr

Convertible Notes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016		Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Amortization of debt discount	$ 495,361		$ 613,121
Unamortized debt discount	(143,419)		(128,047)
Convertible Notes
Additional paid in capital and discount	282,470
Amortization of debt discount	$ 15,156		89,706
Exercise price	$ 0.0058
Unamortized debt discount	$ (8,937)		(31,000)
Convertible notes payable	2,375,000		2,455,000
Convertible Notes | Individually Issued
Convertible notes, sold				$ 300,000
Convertible notes, payment terms				The note pays interest at a rate of 12% per annum, payable to the holder at 1% per month. The Company is making monthly payments of $5,000 towards the principal balance beginning June 1, 2014 until the note due date of February 27, 2018.
Convertible notes, price per share for conversion of shares of common stock				$ 0.15
Convertible notes, interest rate				12.00%
Maturity date				Feb. 27, 2017
Common stock issued				300,000
Convertible notes payable	$ 145,000
Convertible Notes | Series C Notes
Convertible notes, payment terms				Series C Notes bear interest at a rate of 12% per annum, payable to the holder at 1% per month, with principal amount due May 31, 2017.
Convertible notes, price per share for conversion of shares of common stock				$ 0.15
Convertible notes, interest rate				12.00%
Private placement, 12% convertible notes, principal amount			$ 20,000	$ 95,000
Maturity date				May 31, 2017
Common stock issued				240,000
Convertible Notes | Series B Notes
Convertible notes, payment terms					Series B Notes pay interest at a rate of 12% per annum, payable to the holder at 1% per month.
Convertible notes, price per share for conversion of shares of common stock					$ 0.10
Convertible notes, interest rate					12.00%
Private placement, 12% convertible notes, principal amount					$ 2,230,000
Maturity date, description	The holders of $1,840,000 Series B Notes have agreed to extend the maturity date of the debt outstanding to July 1, 2017 from its original maturity date of December 31, 2015. The holders of $50,000 Series B Notes have agreed to extend the maturity date of the debt outstanding to September 1, 2017. The holder of $25,000 Series B Notes has agreed to extend the maturity date of the debt outstanding to September 1, 2019.
Maturity date			Jul. 1, 2017
Common stock issued					5,315,000
Warrants issued, shares	75,000	[1],[2]	1,840,000
Warrants issued, value per share	$ 0.07		$ 0.07
Exercise price			$ 0.0058
Unamortized debt discount	$ 285		$ 10,672
[1]	The 25,000 warrants issued are valued at $0.00583 per issued share.
[2]	The 50,000 warrants issued are valued at $0.00278 per issued share.

Royalty Financing (Details Narr

Royalty Financing (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Royalty Financing
Royalty purchase agreement, amount			$ 2,000,000
Royalty purchase agreement			On October 31, 2014, the Company entered into a royalty purchase agreement with Grenville Strategic Royalty Corp. for the amount of $2,000,000. The agreement calls for a monthly payment to the seller based on a percentage of the total of certain revenue items and subject to a minimum payment amount until $8,000,000 has been paid.
Royalty payments	$ 240,119	$ 410,189
Discounted amortization expense	315,827	340,372
Accrued royalties	181,096
Royalty purchase agreement, balance	2,007,424	1,935,101
Royalty financing, unamortized discount	$ 5,302,853	$ 5,618,680

Income Taxes - Deferred Taxes (

Income Taxes - Deferred Taxes (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Deferred tax asset	$ 1,515,712	$ 1,062,352
Less valuation allowance	(1,515,712)	(1,062,352)
Net deferred tax asset	$ 0	$ 0

Income Taxes - Effective Income

Income Taxes - Effective Income Tax Rate Reconciliation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Expected Provision (based on statutory rate)	$ (453,360)	$ (551,219)
Increase to deferred tax valuation allowance for net operating loss carry forward	453,360	551,219
Net provision	$ 0	$ 0

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	12 Months Ended
	Dec. 31, 2016USD ($)
Income Tax Disclosure [Abstract]
Operating loss carryforward	$ 1,839,366
Operating loss carryforward, expiration	Dec. 31, 2017
Income taxes at statutory tax rates	34.00%

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Common stock issued for services, value	$ 14,000	$ 65,465
Major Shareholder
Consulting services, description		January 2015, the Company entered into an agreement with a company that is owned and controlled by a major shareholder, to provide consulting services. Fees payable for performance of the consulting services are $10,000 per month.
Stock options, granted		4,200,000
Stock options, exercise price		$ 0.15
Stock options, contractual term		5 years
Common stock issued for services		450,000
Common stock issued for services, value		$ 20,250
Balance for services rendered	$ 120,000	$ 120,000

Common Stock Transactions (Deta

Common Stock Transactions (Details Narrative) - USD ($)		12 Months Ended
		Dec. 31, 2016		Dec. 31, 2015
Shares issued for services, value		$ 14,000		$ 65,465
Bridge Convertible Promissory Notes
Shares issued, inducement	[1]	200,000
Shares issued, inducement, value	[2]	$ 9,030
Convertible Notes
Exercise price		$ 0.0058
Convertible Notes | Series C Notes
Shares issued, convertible notes, shares				20,000
Shares issued, convertible notes, value				$ 1,040
Convertible Notes | Series B Notes
Warrants issued, shares		75,000	[3],[4]	1,840,000
Warrants issued, value per share		$ 0.07		$ 0.07
Exercise price				$ 0.0058
Common Stock
Shares issued for services, shares		150,000		1,425,000
Shares issued for services, value		$ 150		$ 1,425
Value of services provided		$ 14,000
Major Shareholder
Stock options, granted				4,200,000
Stock options, exercise price				$ 0.15
Stock options, contractual term				5 years
Stock price at grant date				$ 0.0517
Expected volatility rate				70.00%
Expected term				2 years 6 months
Risk free interest rate				0.03%
Value of stock options at grant date				$ 34,683
Shares issued for services, shares				450,000
Shares issued for services, value				$ 20,250
Chief Executive Officer
Stock options, granted				4,200,000
Stock options, exercise price				$ 0.15
Stock options, contractual term				5 years
Stock price at grant date				$ 0.0517
Expected volatility rate				70.00%
Expected term				2 years 6 months
Risk free interest rate				0.03%
Value of stock options at grant date				$ 34,683
Chief Financial Officer
Stock options, granted				1,600,000
Stock options, exercise price				$ 0.15
Stock options, contractual term				5 years
Stock price at grant date				$ 0.0517
Expected volatility rate				70.00%
Expected term				2 years 6 months
Risk free interest rate				0.03%
Value of stock options at grant date				$ 13,213
[1]	30,000, 70,000 and 100,000 shares issued on June 16, 2016, March 22, 2016 and February 18, 2016 as part of a bridge convertible note to a private investor.
[2]	Shares valued at $609, $1,421 and $7,000 as part of a bridge convertible note to a private investor.
[3]	The 25,000 warrants issued are valued at $0.00583 per issued share.
[4]	The 50,000 warrants issued are valued at $0.00278 per issued share.

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Total Comprehensive Income (Loss)	$ (1,333,411)	$ (1,621,233)
Working capital deficit	$ 5,276,282

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Feb. 28, 2017	Dec. 31, 2016	Dec. 31, 2015
Subsequent Event [Line Items]
Shares issued for Services, value		$ 14,000	$ 65,465
Common Stock
Subsequent Event [Line Items]
Shares issued for Services, value		$ 150	$ 1,425
Shares issued for Services, shares		150,000	1,425,000
Subsequent Event | Common Stock
Subsequent Event [Line Items]
Shares issued for Services, value	$ 30,600
Shares issued for Services, shares	765,000